S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
AAPL   263.19 (-1.16%)
FB   197.51 (-0.91%)
MSFT   149.62 (-0.51%)
GOOGL   1,301.86 (-0.82%)
AMZN   1,745.53 (-0.41%)
CGC   17.64 (+15.14%)
NVDA   211.18 (+1.53%)
MU   45.57 (-2.17%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
TSLA   352.22 (-2.03%)
T   37.18 (-2.16%)
AMD   40.98 (-0.75%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
PRI   131.52 (-0.09%)
NFLX   305.16 (+0.85%)
BAC   32.69 (-0.76%)
GILD   64.88 (-0.18%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
AAPL   263.19 (-1.16%)
FB   197.51 (-0.91%)
MSFT   149.62 (-0.51%)
GOOGL   1,301.86 (-0.82%)
AMZN   1,745.53 (-0.41%)
CGC   17.64 (+15.14%)
NVDA   211.18 (+1.53%)
MU   45.57 (-2.17%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
TSLA   352.22 (-2.03%)
T   37.18 (-2.16%)
AMD   40.98 (-0.75%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
PRI   131.52 (-0.09%)
NFLX   305.16 (+0.85%)
BAC   32.69 (-0.76%)
GILD   64.88 (-0.18%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
AAPL   263.19 (-1.16%)
FB   197.51 (-0.91%)
MSFT   149.62 (-0.51%)
GOOGL   1,301.86 (-0.82%)
AMZN   1,745.53 (-0.41%)
CGC   17.64 (+15.14%)
NVDA   211.18 (+1.53%)
MU   45.57 (-2.17%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
TSLA   352.22 (-2.03%)
T   37.18 (-2.16%)
AMD   40.98 (-0.75%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
PRI   131.52 (-0.09%)
NFLX   305.16 (+0.85%)
BAC   32.69 (-0.76%)
GILD   64.88 (-0.18%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
AAPL   263.19 (-1.16%)
FB   197.51 (-0.91%)
MSFT   149.62 (-0.51%)
GOOGL   1,301.86 (-0.82%)
AMZN   1,745.53 (-0.41%)
CGC   17.64 (+15.14%)
NVDA   211.18 (+1.53%)
MU   45.57 (-2.17%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
TSLA   352.22 (-2.03%)
T   37.18 (-2.16%)
AMD   40.98 (-0.75%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
PRI   131.52 (-0.09%)
NFLX   305.16 (+0.85%)
BAC   32.69 (-0.76%)
GILD   64.88 (-0.18%)
DIS   146.93 (-0.98%)
Log in

Antares Pharma Stock Price, Forecast & Analysis (NASDAQ:ATRS)

$4.62
+0.18 (+4.05 %)
(As of 11/20/2019 04:00 PM ET)
Today's Range
$4.42
Now: $4.62
$4.73
50-Day Range
$3.23
MA: $3.55
$4.49
52-Week Range
$2.53
Now: $4.62
$4.74
Volume3.44 million shs
Average Volume1.12 million shs
Market Capitalization$754.10 million
P/E RatioN/A
Dividend YieldN/A
Beta0.8
Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:ATRS
CUSIP03664210
Phone609-359-3020

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$63.55 million
Book Value$0.25 per share

Profitability

Net Income$-6,510,000.00

Miscellaneous

Employees165
Market Cap$754.10 million
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive ATRS News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRS and its competitors with MarketBeat's FREE daily newsletter.


Antares Pharma (NASDAQ:ATRS) Frequently Asked Questions

What is Antares Pharma's stock symbol?

Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."

How were Antares Pharma's earnings last quarter?

Antares Pharma Inc (NASDAQ:ATRS) posted its quarterly earnings data on Tuesday, November, 5th. The specialty pharmaceutical company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.03. The specialty pharmaceutical company earned $34.31 million during the quarter, compared to analyst estimates of $26.36 million. Antares Pharma had a negative net margin of 0.56% and a negative return on equity of 1.40%. View Antares Pharma's Earnings History.

When is Antares Pharma's next earnings date?

Antares Pharma is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Antares Pharma.

What price target have analysts set for ATRS?

3 brokers have issued 1-year price objectives for Antares Pharma's stock. Their forecasts range from $1.99 to $5.65. On average, they anticipate Antares Pharma's share price to reach $4.05 in the next year. This suggests that the stock has a possible downside of 12.4%. View Analyst Price Targets for Antares Pharma.

What is the consensus analysts' recommendation for Antares Pharma?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Antares Pharma in the last year. There are currently 2 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Antares Pharma.

Has Antares Pharma been receiving favorable news coverage?

Media headlines about ATRS stock have been trending neutral this week, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Antares Pharma earned a media sentiment score of 0.0 on InfoTrie's scale. They also gave media stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Antares Pharma.

Are investors shorting Antares Pharma?

Antares Pharma saw a decline in short interest in October. As of October 31st, there was short interest totalling 4,040,000 shares, a decline of 10.0% from the September 30th total of 4,490,000 shares. Based on an average daily volume of 994,700 shares, the days-to-cover ratio is currently 4.1 days. Currently, 2.7% of the company's shares are short sold. View Antares Pharma's Current Options Chain.

Who are some of Antares Pharma's key competitors?

What other stocks do shareholders of Antares Pharma own?

Who are Antares Pharma's key executives?

Antares Pharma's management team includes the folowing people:
  • Mr. Robert F. Apple, CEO, Pres & Director (Age 53)
  • Mr. Fred M. Powell, Exec. VP & CFO (Age 58)
  • Mr. Peter J. Graham, Exec. VP of HR, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 52)
  • Dr. James Patrick Tursi, EVP, Head of R&D & Chief Medical Officer (Age 54)
  • Mr. Keith Muckenhirn, Principal Accounting Officer, VP of Fin. & Corp. Controller (Age 56)

Who are Antares Pharma's major shareholders?

Antares Pharma's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Sargent Investment Group LLC (2.04%), State of New Jersey Common Pension Fund D (0.47%), Perkins Capital Management Inc. (0.19%), California Public Employees Retirement System (0.16%), Monarch Partners Asset Management LLC (0.10%) and Envestnet Asset Management Inc. (0.03%). Company insiders that own Antares Pharma stock include Jacques Gonella, Leonard S Jacob, Robert F Apple and Thomas J Garrity. View Institutional Ownership Trends for Antares Pharma.

Which institutional investors are selling Antares Pharma stock?

ATRS stock was sold by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc. and SG Americas Securities LLC. Company insiders that have sold Antares Pharma company stock in the last year include Jacques Gonella, Leonard S Jacob and Thomas J Garrity. View Insider Buying and Selling for Antares Pharma.

Which institutional investors are buying Antares Pharma stock?

ATRS stock was bought by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Sargent Investment Group LLC, Monarch Partners Asset Management LLC, California Public Employees Retirement System, Russell Investments Group Ltd., Cadence Capital Management LLC, CWM LLC and Envestnet Asset Management Inc.. View Insider Buying and Selling for Antares Pharma.

How do I buy shares of Antares Pharma?

Shares of ATRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Antares Pharma's stock price today?

One share of ATRS stock can currently be purchased for approximately $4.62.

How big of a company is Antares Pharma?

Antares Pharma has a market capitalization of $754.10 million and generates $63.55 million in revenue each year. The specialty pharmaceutical company earns $-6,510,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis. Antares Pharma employs 165 workers across the globe.View Additional Information About Antares Pharma.

What is Antares Pharma's official website?

The official website for Antares Pharma is http://www.antarespharma.com/.

How can I contact Antares Pharma?

Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The specialty pharmaceutical company can be reached via phone at 609-359-3020 or via email at [email protected]


MarketBeat Community Rating for Antares Pharma (NASDAQ ATRS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  341 (Vote Outperform)
Underperform Votes:  263 (Vote Underperform)
Total Votes:  604
MarketBeat's community ratings are surveys of what our community members think about Antares Pharma and other stocks. Vote "Outperform" if you believe ATRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel